Show/hide main menu

News

Wednesday 12th October 2016

New study shows role of protein in rheumatoid arthritis susceptibility

New study shows role of protein in rheumatoid arthritis susceptibility
Description
A new study conducted by researchers in the Faculty and funded by Arthritis UK has shed light on how a genetic mutation in the protein that affects T cell responsiveness (PTPN22) could play a key role in the development of rheumatoid arthritis.
Date:
12 October 2016
Tuesday 27th September 2016

Funding for new immunotherapy company

Funding for new immunotherapy company
Description
A new immunotherapy company, founded on pioneering work by researchers at King's College London and the Francis Crick Institute, has received seed funding from Abingworth, the international investment group dedicated to life sciences. The company has also received support from Cancer Research Technology (CRT), King's College London and the Francis Crick Institute.
Date:
27 September 2016
Tuesday 3rd May 2016

Professor Adrian Hayday elected to the fellowship of the Royal Society

Description
Professor Adrian Hayday from the Division of Immunology, Infection & Inflammatory Disease in the Faculty, has been elected to the fellowship of the Royal Society, the UK's national academy of science. 50 Fellows are elected each year in recognition of their exceptional contributions to science, engineering and medicine.
Date:
03 May 2016
Wednesday 17th February 2016

New public and private partnership launched to tackle type 1 diabetes

New public and private partnership launched to tackle type 1 diabetes
Description
King's College London has joined a public private partnership (PPP) aimed at significantly improving the understanding of type 1 diabetes (T1D) and to work towards better therapies for preventing and curing the disease. The INNODIA consortium is made up of 33 partners from academia, medium-sized enterprises (SME), large pharmaceutical companies and patient organisations and has received €36.5 million funding to carry out its work.
Date:
17 February 2016
Monday 25th January 2016

King's signs agreement with Pfizer in field of gene therapy

King's signs agreement with Pfizer in field of gene therapy
Description
King's College London has announced that it has recently entered into an exclusive license agreement with Pfizer Inc. for the development of a series of adeno-associated virus (AAV) gene therapy vectors. This programme emerges from technology developed by Professor Michael Linden and Dr Els Henckaerts from the Division of Immunology, Infection & Inflammatory Disease.
Date:
25 January 2016
Displaying 1 to 5 of 31
Previous 1 2 3 4 5 Next
Sitemap Site help Terms and conditions  Privacy policy  Accessibility  Modern slavery statement  Contact us

© 2019 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454